Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer

Wei Yu Chen, Tao Zeng, Yu Chng Wen, Hsiu Lien Yeh, Kuo Ching Jiang, Wei Hao Chen, Qingfu Zhang, Jiaoti Huang, Yen Nien Liu

研究成果: 雜誌貢獻文章

2 引文 (Scopus)

摘要

Androgen receptor (AR) targeting is an important therapeutic strategy for treating prostate cancer. Most tumors progress to castration-resistant prostate cancer (CRPC) and develop the neuroendocrine (NE) phenotype under androgen deprivation therapy (ADT). The molecular basis for NE transdifferentiation after ADT remains incompletely understood. Herein, we show that an immunocyte expression protein, ZBTB46, induces inflammatory response gene expression and contributes to NE differentiation of prostate cancer cells. We demonstrated a molecular mechanism whereby ZBTB46 can be regulated by the androgen-responsive gene, SPDEF, and is associated with NE prostate cancer (NEPC) differentiation. In addition, ZBTB46 acts as a transcriptional coactivator that binds to the promoter of prostaglandin-endoperoxide synthase 1 (PTGS1) and transcriptionally regulated PTGS1 levels. Overexpression of ZBTB46 decreases the sensitivity of the combination of enzalutamide and a PTGS1 inhibitor; however, knockdown of ZBTB46 sensitizes the PTGS1 inhibitor and reduces tumor malignancy. ZBTB46 is inversely correlated with SPDEF and is increased in higher tumor grades and small-cell NE prostate cancer (SCNC) patients, which are positively associated with PTGS1. Our findings suggest that the induction of ZBTB46 results in increased PTGS1 expression, which is associated with NEPC progression and linked to the dysregulation of the AR-SPDEF pathway.
原文英語
頁(從 - 到)35-46
頁數12
期刊Cancer Letters
440-441
DOIs
出版狀態已發佈 - 一月 1 2019

指紋

Prostaglandin-Endoperoxide Synthases
Androgens
Prostatic Neoplasms
Cyclooxygenase Inhibitors
Androgen Receptors
Neoplasms
Neuroendocrine Cells
Castration
Therapeutics
Phenotype
Gene Expression
Genes
Proteins

Keywords

  • Androgen deprivation therapy (ADT)
  • Neuroendocrine prostate cancer (NEPC)
  • PTGS1
  • SPDEF
  • ZBTB46

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer. / Chen, Wei Yu; Zeng, Tao; Wen, Yu Chng; Yeh, Hsiu Lien; Jiang, Kuo Ching; Chen, Wei Hao; Zhang, Qingfu; Huang, Jiaoti; Liu, Yen Nien.

於: Cancer Letters, 卷 440-441, 01.01.2019, p. 35-46.

研究成果: 雜誌貢獻文章

Chen, Wei Yu ; Zeng, Tao ; Wen, Yu Chng ; Yeh, Hsiu Lien ; Jiang, Kuo Ching ; Chen, Wei Hao ; Zhang, Qingfu ; Huang, Jiaoti ; Liu, Yen Nien. / Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer. 於: Cancer Letters. 2019 ; 卷 440-441. 頁 35-46.
@article{e0303364940748e6abe5aa8d140bbbbe,
title = "Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer",
abstract = "Androgen receptor (AR) targeting is an important therapeutic strategy for treating prostate cancer. Most tumors progress to castration-resistant prostate cancer (CRPC) and develop the neuroendocrine (NE) phenotype under androgen deprivation therapy (ADT). The molecular basis for NE transdifferentiation after ADT remains incompletely understood. Herein, we show that an immunocyte expression protein, ZBTB46, induces inflammatory response gene expression and contributes to NE differentiation of prostate cancer cells. We demonstrated a molecular mechanism whereby ZBTB46 can be regulated by the androgen-responsive gene, SPDEF, and is associated with NE prostate cancer (NEPC) differentiation. In addition, ZBTB46 acts as a transcriptional coactivator that binds to the promoter of prostaglandin-endoperoxide synthase 1 (PTGS1) and transcriptionally regulated PTGS1 levels. Overexpression of ZBTB46 decreases the sensitivity of the combination of enzalutamide and a PTGS1 inhibitor; however, knockdown of ZBTB46 sensitizes the PTGS1 inhibitor and reduces tumor malignancy. ZBTB46 is inversely correlated with SPDEF and is increased in higher tumor grades and small-cell NE prostate cancer (SCNC) patients, which are positively associated with PTGS1. Our findings suggest that the induction of ZBTB46 results in increased PTGS1 expression, which is associated with NEPC progression and linked to the dysregulation of the AR-SPDEF pathway.",
keywords = "Androgen deprivation therapy (ADT), Neuroendocrine prostate cancer (NEPC), PTGS1, SPDEF, ZBTB46, Androgen deprivation therapy (ADT), Neuroendocrine prostate cancer (NEPC), PTGS1, SPDEF, ZBTB46",
author = "Chen, {Wei Yu} and Tao Zeng and Wen, {Yu Chng} and Yeh, {Hsiu Lien} and Jiang, {Kuo Ching} and Chen, {Wei Hao} and Qingfu Zhang and Jiaoti Huang and Liu, {Yen Nien}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2018.10.004",
language = "English",
volume = "440-441",
pages = "35--46",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer

AU - Chen, Wei Yu

AU - Zeng, Tao

AU - Wen, Yu Chng

AU - Yeh, Hsiu Lien

AU - Jiang, Kuo Ching

AU - Chen, Wei Hao

AU - Zhang, Qingfu

AU - Huang, Jiaoti

AU - Liu, Yen Nien

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Androgen receptor (AR) targeting is an important therapeutic strategy for treating prostate cancer. Most tumors progress to castration-resistant prostate cancer (CRPC) and develop the neuroendocrine (NE) phenotype under androgen deprivation therapy (ADT). The molecular basis for NE transdifferentiation after ADT remains incompletely understood. Herein, we show that an immunocyte expression protein, ZBTB46, induces inflammatory response gene expression and contributes to NE differentiation of prostate cancer cells. We demonstrated a molecular mechanism whereby ZBTB46 can be regulated by the androgen-responsive gene, SPDEF, and is associated with NE prostate cancer (NEPC) differentiation. In addition, ZBTB46 acts as a transcriptional coactivator that binds to the promoter of prostaglandin-endoperoxide synthase 1 (PTGS1) and transcriptionally regulated PTGS1 levels. Overexpression of ZBTB46 decreases the sensitivity of the combination of enzalutamide and a PTGS1 inhibitor; however, knockdown of ZBTB46 sensitizes the PTGS1 inhibitor and reduces tumor malignancy. ZBTB46 is inversely correlated with SPDEF and is increased in higher tumor grades and small-cell NE prostate cancer (SCNC) patients, which are positively associated with PTGS1. Our findings suggest that the induction of ZBTB46 results in increased PTGS1 expression, which is associated with NEPC progression and linked to the dysregulation of the AR-SPDEF pathway.

AB - Androgen receptor (AR) targeting is an important therapeutic strategy for treating prostate cancer. Most tumors progress to castration-resistant prostate cancer (CRPC) and develop the neuroendocrine (NE) phenotype under androgen deprivation therapy (ADT). The molecular basis for NE transdifferentiation after ADT remains incompletely understood. Herein, we show that an immunocyte expression protein, ZBTB46, induces inflammatory response gene expression and contributes to NE differentiation of prostate cancer cells. We demonstrated a molecular mechanism whereby ZBTB46 can be regulated by the androgen-responsive gene, SPDEF, and is associated with NE prostate cancer (NEPC) differentiation. In addition, ZBTB46 acts as a transcriptional coactivator that binds to the promoter of prostaglandin-endoperoxide synthase 1 (PTGS1) and transcriptionally regulated PTGS1 levels. Overexpression of ZBTB46 decreases the sensitivity of the combination of enzalutamide and a PTGS1 inhibitor; however, knockdown of ZBTB46 sensitizes the PTGS1 inhibitor and reduces tumor malignancy. ZBTB46 is inversely correlated with SPDEF and is increased in higher tumor grades and small-cell NE prostate cancer (SCNC) patients, which are positively associated with PTGS1. Our findings suggest that the induction of ZBTB46 results in increased PTGS1 expression, which is associated with NEPC progression and linked to the dysregulation of the AR-SPDEF pathway.

KW - Androgen deprivation therapy (ADT)

KW - Neuroendocrine prostate cancer (NEPC)

KW - PTGS1

KW - SPDEF

KW - ZBTB46

KW - Androgen deprivation therapy (ADT)

KW - Neuroendocrine prostate cancer (NEPC)

KW - PTGS1

KW - SPDEF

KW - ZBTB46

UR - http://www.scopus.com/inward/record.url?scp=85054904049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054904049&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2018.10.004

DO - 10.1016/j.canlet.2018.10.004

M3 - Article

VL - 440-441

SP - 35

EP - 46

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -